Experimental antibody drug aims to tackle stubborn high blood pressure

NCT ID NCT06833190

Terminated Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called REGN5381 in 34 adults with uncontrolled hypertension (high blood pressure despite taking one or more blood pressure medications). The drug is a monoclonal antibody designed to activate NPR1 receptors, which may help lower blood pressure. The trial was a Phase 2b, randomized, double-blind, placebo-controlled study, but it was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN5381 (a monoclonal antibody that targets NPR1 receptors to help lower blood pressure)
What this could lead to: If it works, this could offer a new treatment option for people whose high blood pressure is not controlled by current medications.
What could go wrong: This was a small, early-phase trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNCONTROLLED HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNCONTROLLED HYPERTENSION

Contacts and locations

Locations

Protas, Car Park of Asda Huyton Supercentre

Huyton, Liverpool, L36 7TX, United Kingdom
Protas, Car Park of Asda Pilsworth Road

Bury, BL9 8RS, United Kingdom
Protas, Two New Bailey Square

Salford, Manchester, M3 5GS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.